Journal of Obesity
Volume 2019 (2019), Article ID 6189724, 2 pages
https://doi.org/10.1155/2019/6189724

Erratum

Erratum to “Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects”

Ralf Uebelhack,¹ Udo Bongartz,¹ Stephanie Seibt,² Gordana Bothe,² Pee Win Chong,³ Patricia De Costa,⁴ and Natalia Wszelaki³

¹Analyze & Realize GmbH, Weißenseer Weg 111, 10369 Berlin, Germany
²Analyze & Realize GmbH, Waldseeweg 6, 13467 Berlin, Germany
³Zaluvida Corporate Sdn Bhd, E-16 Plaza Mont Kiara, 2 Jalan Kiara, 50480 Kuala Lumpur, Malaysia
⁴InQpharm Group Sdn Bhd, E-16 Plaza Mont Kiara, 2 Jalan Kiara, 50480 Kuala Lumpur, Malaysia

Correspondence should be addressed to Patricia De Costa; patricia@inqpharm.com

Received 8 May 2019; Accepted 12 May 2019; Published 11 July 2019

Copyright © 2019 Ralf Uebelhack et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects” [1], there was an error in the legend of Figure 3 that occurred during the production stage, as the color of the placebo results/bars has been replaced by the colors of the high dose results/bars and vice versa.

The correct version of Figure 3 should be as follows:

Figure 3: Responder rate for subjects who lost ≥3% and ≥5% of initial body weight at v6. LD = low dose; HD = high dose. a vs. placebo; b vs. placebo; c vs. low-dose group.

References

R. Uebelhack, U. Bongartz, S. Seibt et al., “Double-blind, randomized, three-armed, placebo-controlled, clinical investigation to evaluate the benefit and tolerability of two dosages of IQP-AE-103 in reducing body weight in overweight and moderately obese subjects,” Journal of Obesity, vol. 2019, Article ID 3412952, 12 pages, 2019.